Thrombophilia and Reproductive Immunology
Ensuring Blood Flow for Success
Thrombophilia management at Gynatal Clinic (Timișoara & Arad) is a vital component for successful embryo implantation and placental health. Led by Dr. Ghilezan Florica, our specialized protocols identify genetic and acquired risks (such as Factor V Leiden, MTHFR, APS). By integrating personalized LMWH (Clexane/Innohep) therapy with IVF, we minimize micro-clot risks and recurrent pregnancy loss, achieving high success in complex cases.
The Impact of Coagulation on the Fertility Flywheel
In reproductive medicine, blood is not merely a transport medium; it is the foundation for the functional connection between mother and fetus. During IVF (FIV) stimulation, the body undergoes significant hormonal changes that naturally increase hypercoagulability (blood stickiness).
Micro-thrombosis and Implantation Failure
If a patient has a hereditary or acquired predisposition to thrombophilia, micro-clots (micro-thrombosis) can form in the small vessels of the uterine lining. These clots block the supply of nutrients and oxygen to the embryo, leading to Recurrent Implantation Failure (RIF)—a situation where high-quality embryos fail to attach despite a perfect laboratory environment.
Precision Diagnostics: Who Should Be Tested?
Following the "Scientific Gold Standard," Gynatal does not perform universal screening. Instead, we utilize targeted testing based on medical history to reduce cognitive friction and unnecessary financial costs for the patient:
- Recurrent Pregnancy Loss (RPL): Two or more consecutive pregnancy losses.
- Repeated IVF Failure: Unsuccessful transfers involving top-grade blastocysts.
- Medical History: A personal or family history of deep vein thrombosis (DVT) or pulmonary embolism.
- Specific Risk Markers: Screening for Factor V Leiden, Prothrombin G20210A, MTHFR mutations, and Antiphospholipid Syndrome (APS).
Therapeutic Management with Dr. Ghilezan Florica
Thrombophilia treatment at Gynatal is seamlessly integrated into the Embryo Transfer (ET) protocol. Our specialist, Dr. Ghilezan Florica (Senior Haematologist), designs individualized schemes including:
Anticoagulant Protocols (LMWH)
The administration of low-molecular-weight heparin (LMWH)typically begins on the day of the transfer. Dosing is precisely adjusted based on the patient’s weight and ongoing coagulation monitoring (D-Dimers, APTT).
Monitoring Throughout the First Trimester
Care does not end with a positive Beta-HCG test. Patients with thrombophilia require increased surveillance throughout the first trimester to ensure the placenta develops in an optimal vascular environment, free from the risk of placental infarction..